Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Testicular Neoplasms 30Testicular Germ Cell Tumor 17Prostatic Neoplasms 13Wilms Tumor 12Teratoma 12Ovarian Neoplasms 11Kidney Neoplasms 9Seminoma 8Endodermal Sinus Tumor 8Sarcoma 7Neuroectodermal Tumors, Primitive, Peripheral 7Central Nervous System Neoplasms 7Carcinoma, Embryonal 7Ovarian Germ Cell Cancer 6Carcinoma, Renal Cell 6Urinary Bladder Neoplasms 4Osteosarcoma 4Neuroblastoma 4Neoplasms 4Melanoma 4Medulloblastoma 4Small Cell Lung Carcinoma 3Rhabdoid Tumor 3Retinoblastoma 3Optic Nerve Glioma 3Neoplasms, Germ Cell and Embryonal 3Lung Neoplasms 3Hepatoblastoma 3Breast Neoplasms 3Astrocytoma 3

Interventions

Docetaxel 4radium Ra 223 dichloride 2Prednisone 2sargramostim 1gossypol acetic acid 1epothilone B 1cabazitaxel 1bafetinib 1Sunitinib 1PE regimen 1Mycobacterium w vaccine 1Interleukin-2 1Injections 1Everolimus 1Etoposide 1Denosumab 1Cyclophosphamide 1Cisplatin 1Carboplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone Refractory Prostate Cancer × Etoposide × Genitourinary × Clear all
NCT02208583 2014-08-05

Molecular Phenotype Changes and Personalized Treatment for CRPC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
150 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡